Brown Miller Wealth Management LLC Has $1.91 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Brown Miller Wealth Management LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,703 shares of the medical research company’s stock after buying an additional 71 shares during the quarter. Brown Miller Wealth Management LLC’s holdings in Amgen were worth $1,905,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. BOK Financial Private Wealth Inc. acquired a new position in Amgen during the fourth quarter worth $29,000. United Community Bank acquired a new position in Amgen during the fourth quarter worth $29,000. Planned Solutions Inc. acquired a new position in Amgen during the fourth quarter worth $30,000. Delos Wealth Advisors LLC increased its position in Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the last quarter. Finally, Hartford Financial Management Inc. increased its position in Amgen by 56.9% during the fourth quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after buying an additional 41 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the subject of a number of recent analyst reports. Royal Bank of Canada upped their price target on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a report on Friday, June 14th. Mizuho upped their price target on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Morgan Stanley upped their price target on shares of Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, May 3rd. Finally, Raymond James initiated coverage on shares of Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $307.35.

Amgen Price Performance

NASDAQ:AMGN traded down $1.24 during mid-day trading on Friday, hitting $312.45. The company’s stock had a trading volume of 3,518,174 shares, compared to its average volume of 2,437,626. Amgen Inc. has a fifty-two week low of $218.44 and a fifty-two week high of $329.72. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The company has a market capitalization of $167.61 billion, a price-to-earnings ratio of 44.64, a P/E/G ratio of 2.82 and a beta of 0.60. The stock has a fifty day moving average of $301.56 and a 200-day moving average of $292.23.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. During the same quarter in the prior year, the business posted $3.98 earnings per share. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. As a group, equities analysts forecast that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.